A detailed history of Swiss National Bank transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Swiss National Bank holds 155,600 shares of RNA stock, worth $7.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
155,600
Previous 156,400 0.51%
Holding current value
$7.02 Million
Previous $6.39 Million 11.87%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$37.21 - $48.14 $29,768 - $38,512
-800 Reduced 0.51%
155,600 $7.15 Million
Q2 2024

Aug 08, 2024

BUY
$22.73 - $40.85 $354,588 - $637,260
15,600 Added 11.08%
156,400 $6.39 Million
Q1 2024

May 07, 2024

BUY
$9.16 - $25.52 $219,840 - $612,480
24,000 Added 20.55%
140,800 $3.59 Million
Q4 2023

Feb 06, 2024

SELL
$4.87 - $9.37 $37,499 - $72,149
-7,700 Reduced 6.18%
116,800 $1.06 Million
Q3 2023

Nov 08, 2023

SELL
$6.3 - $11.35 $40,950 - $73,775
-6,500 Reduced 4.96%
124,500 $794,000
Q2 2023

Aug 09, 2023

BUY
$10.62 - $17.34 $172,044 - $280,908
16,200 Added 14.11%
131,000 $1.45 Million
Q1 2023

May 10, 2023

SELL
$15.35 - $25.65 $300,860 - $502,740
-19,600 Reduced 14.58%
114,800 $1.76 Million
Q4 2022

Feb 08, 2023

BUY
$10.06 - $22.66 $461,754 - $1.04 Million
45,900 Added 51.86%
134,400 $2.98 Million
Q3 2022

Nov 09, 2022

BUY
$15.46 - $23.43 $81,938 - $124,179
5,300 Added 6.37%
88,500 $1.45 Million
Q1 2022

May 09, 2022

BUY
$14.2 - $23.78 $113,600 - $190,240
8,000 Added 10.64%
83,200 $1.54 Million
Q3 2021

Nov 08, 2021

BUY
$18.16 - $25.21 $690,080 - $957,980
38,000 Added 102.15%
75,200 $1.85 Million
Q2 2021

Aug 06, 2021

BUY
$19.62 - $29.26 $147,150 - $219,450
7,500 Added 25.25%
37,200 $919,000
Q4 2020

Feb 05, 2021

BUY
$24.73 - $35.12 $734,481 - $1.04 Million
29,700 New
29,700 $758,000

Others Institutions Holding RNA

About Avidity Biosciences, Inc.


  • Ticker RNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,127,000
  • Market Cap $2.35B
  • Description
  • Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...
More about RNA
Track This Portfolio

Track Swiss National Bank Portfolio

Follow Swiss National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.